Evidence Hub

Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective

Nour H. Marzouk, Hannah H. Rashwan, Mohamed El-Hadidi, Raghda Ramadan, Mohamed Mysara

npj Parkinson's Disease, 2025

15 citations

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by motor dysfunction coupled with gastrointestinal disturbances. Recent studies implicate the gut microbiome with the development of PD, yet pinpointing the exact microbial players is still to be determined. This meta-analysis is the first to consolidate five homogenous case-control studies, covering the same variable regions of the 16S rRNA of 1007 fecal samples. Utilizing our unified pipeline, we identified several key players potentially contributing to PD. Our findings reveal higher microbial diversity characterized by elevated levels GABA consuming species particularly Evtepia gabavorous, contributing to neuronal excitability. We also report the abundance of the proinflammatory Klebsiella variicola and the H2S-producing Streptococcus anginosus bacteria, potentially promoting α-synuclein accumulation in the brain. This comprehensive analysis highlights the potential of gut microbiota as a biomarker and a therapeutic strategy to mitigate the progression of PD, possibly facilitating diagnosis and enhancing patient outcomes.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free